Trademark Search in Canada

ANIMA BIOTECH

View On IC.GC.CA

REGISTERED

on 31 May 2024

Last Applicant/ Owned by

ANIMA BIOTECH INC.

75 Claremont Rd, Ste 102Bernardsville NJ 07924

Serial Number

2143287 filed on 8^th Aug 2021

Registration Number

TMA1235687 registered on 31^st May 2024

Registration expiry Date

8^th Aug 2031

Correspondent Address

SMART & BIGGAR LP

SUITE 1000, 55 METCALFE STREETP.O. BOX 2999, STATION DOTTAWA

ONTARIO

K1P5Y6

ANIMA BIOTECH

Trademark usage description

pharmaceuticals, namely, small molecules therapeutic preparations for the regulation of mrna translation and mrna biology, used in the treatment of fi Read More

Vienna Information

26 . 15 . 1

SpheresSphères

26 . 11 . 1

One line or one bandUne ligne ou une bande

26 . 11 . 2

Two lines or bandsDeux lignes ou bandes

26 . 11 . 12

Curved lines or bands (except a 26.11.13)Lignes ou bandes courbes (excepté a 26.11.13)

Classification Information

Class [005]
Pharmaceuticals, namely, small molecules therapeutic preparations for the regulation of mRNA translation and mRNA biology, used in the treatment of fibrosis, cancers, neurological diseases, infectious diseases, genetic diseases, diseases and disorders of the cardiovascular system, diseases and disorders of the digestive system, diseases and disorders of the endocrine system, diseases and disorders of the immune system, diseases and disorders of the integumentary system, diseases and disorders of the lymphatic system, diseases and disorders of the respiratory system, diseases and disorders relating to sexual reproduction and fertility, diseases and disorders of the muscular system, skeletal diseases and disorders, renal and urological disease and disorders, metabolic diseases, and inflammatory diseases; pharmaceutical and medical preparations and substances for the treatment of fibrosis, cancers, neurological diseases, infectious diseases, genetic diseases, diseases and disorders of the cardiovascular system, diseases and disorders of the digestive system, diseases and disorders of the endocrine system, diseases and disorders of the immune system, diseases and disorders of the integumentary system, diseases and disorders of the lymphatic system, diseases and disorders of the respiratory system, diseases and disorders relating to sexual reproduction and fertility, diseases and disorders of the muscular system, skeletal diseases and disorders, renal and urological disease and disorders, metabolic diseases, and inflammatory diseases; medical and pharmaceutical chemical preparations for the treatment of fibrosis, cancers, neurological diseases, infectious diseases, genetic diseases, diseases and disorders of the cardiovascular system, diseases and disorders of the digestive system, diseases and disorders of the endocrine system, diseases and disorders of the immune system, diseases and disorders of the integumentary system, diseases and disorders of the lymphatic system, diseases and disorders of the respiratory system, diseases and disorders relating to sexual reproduction and fertility, diseases and disorders of the muscular system, skeletal diseases and disorders, renal and urological disease and disorders, metabolic diseases, and inflammatory diseases; pharmaceutical preparations for RNA targeted therapeutics for the treatment of fibrosis, cancers, neurological diseases, infectious diseases, genetic diseases, diseases and disorders of the cardiovascular system, diseases and disorders of the digestive system, diseases and disorders of the endocrine system, diseases and disorders of the immune system, diseases and disorders of the integumentary system, diseases and disorders of the lymphatic system, diseases and disorders of the respiratory system, diseases and disorders relating to sexual reproduction and fertility, diseases and disorders of the muscular system, skeletal diseases and disorders, renal and urological disease and disorders, metabolic diseases, and inflammatory diseases; therapeutic agents for acting on protein targets that regulate translational control of gene expression for the treatment of fibrosis, cancers, neurological diseases, infectious diseases, genetic diseases, diseases and disorders of the cardiovascular system, diseases and disorders of the digestive system, diseases and disorders of the endocrine system, diseases and disorders of the immune system, diseases and disorders of the integumentary system, diseases and disorders of the lymphatic system, diseases and disorders of the respiratory system, diseases and disorders relating to sexual reproduction and fertility, diseases and disorders of the muscular system, skeletal diseases and disorders, renal and urological disease and disorders, metabolic diseases, and inflammatory diseases.

Classification kind code

Class [042]
Research and development of pharmaceuticals, namely, small molecule therapeutic preparations for the regulation of mRNA translation and mRNA biology, used in the treatment of fibrosis, cancers, neurological diseases, infectious diseases, genetic diseases, and other diseases; research and development of pharmaceutical preparations; pharmaceutical drug development services; providing scientific research information in the field of pharmaceuticals and molecular biology; research, analysis, and development in the field of pharmaceutical; research and development in the field of bio-therapeutics for the treatment of fibrosis, cancers, neurological diseases, infectious diseases, genetic diseases, and other diseases; scientific investigations for medical purposes; pharmaceutical research and development, medical research, and scientific research and development, namely research and development of testing methods, treatments, and products; pharmaceutical, medical and scientific drug development and discovery; scientific and technological services and research relating to the field of pharmaceuticals.

Classification kind code

Mark Details

Serial Number

2143287

Mark Type

Trademark

Legal History

Action Taken	Status
Submitted for opposition 48 on 21^st Mar 2023	Agent Changed
Submitted for opposition 22 on 20^th Feb 2023	Search Recorded
Submitted for opposition 20 on 20^th Feb 2023	Examiner's First Report
Submitted for opposition 223 on 20^th Feb 2023	Total Provisional Refusal
Submitted for opposition 256 on 29^th Aug 2022	Notification of Possible Opposition Sent
Submitted for opposition 257 on 28^th Oct 2021	Designation Notification - Madrid Protocol
Submitted for opposition 31 on 27^th Oct 2021	Formalized
Submitted for opposition 1 on 27^th Oct 2021	Created
Submitted for opposition 228 on 8^th Aug 2021	International Registration
Submitted for opposition 30 on 8^th Aug 2021	Filed